Fig. 1 · Structure

Documents & Downloads

SB 525334

Cat. No. A10827 CAS 356559-20-1

ALK Inhibitor

SB525334 is a selective inhibitor of transforming growth factor-β receptor I (ALK5, TGF-βRI) (IC50 = 14.3 nM). Inhibits TGF-β1-induced smad2/3 nuclear localization and TGF-βRI-induced mRNA expression in kidney cells

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
TGFβR1(ALK5) (Cell-free assay) 14.3 nM

In Vitro Studies

Differentiating L2A(−) 3T3L1 cells received treatment at 1 μM for 12 hours at day 1.5. Treatment partially rescued the adipogenic defect compared with untreated cells, assessed by DPH staining and quantification of differentiated cells at day 7. Model: healthy lung alveolar fibroblasts. Treatment: 1 µM. Result: CD44Hi SftpcC121G AT2 conditioned media stimulates fibrotic marker gene (Cthrc1, Col1a1) expression, which is attenuated by ALK-5 inhibition.. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Partial rescue of an adipogenic defect

Cell-based study · L2A(−) 3T3L1 cells [1]

Differentiating L2A(−) 3T3L1 cells received treatment at 1 μM for 12 hours at day 1.5. Treatment partially rescued the adipogenic defect compared with untreated cells, assessed by DPH staining and quantification of differentiated cells at day 7.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DPH staining and quantification of percentage of differentiated cells in 3T3L1 cells at day 7Reported result partially rescue the adipogenic defect of L2A(−) cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
for 12 hours at day 1.5
Method
added to differentiating cells
Co-treatment
Other interventions in this design: insulin 160 nM; dexamethasone 250 nM; 1-methyl-3-isobutylxanthine 0.5 mM. Compound effect isolated by the comparison: untreated or treated with TGFβ inhibitor.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: SB 525334

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Timed inhibition of TGFβ/SMAD signaling by CMA is required for adipocyte differentiation (S134); MATERIALS AND METHODS > Cell treatments (S159, S164); MATERIALS AND METHODS > Cell imaging (S168); Fig. 6. legend (S323, S324)

DPH staining and quantification of percentage of differentiated cells in 3T3L1 cells at day 7: DPH staining and quantification of percentage of differentiated cells in 3T3L1 cells at day 7; comparator: untreated — RESULTS > Timed inhibition of TGFβ/SMAD signaling by CMA is required for adipocyte differentiation (S134); Fig. 6. legend (S324)

RT-qPCR gene expression of alveolar fibroblasts in healthy lung alveolar fibroblasts

Cell-based study · healthy lung alveolar fibroblasts [2]

Model: healthy lung alveolar fibroblasts. Treatment: 1 µM. Result: CD44Hi SftpcC121G AT2 conditioned media stimulates fibrotic marker gene (Cthrc1, Col1a1) expression, which is attenuated by ALK-5 inhibition..

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RT-qPCR gene expression of alveolar fibroblastsReported result CD44Hi SftpcC121G AT2 conditioned media stimulates fibrotic marker gene (Cthrc1, Col1a1) expression, which is attenuated by ALK-5 inhibition.[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
2 days
Method
added to conditioned media
Co-treatment
Other interventions in this design: CD44Hi SftpcC121G AT2 conditioned media. Compound effect isolated by the comparison: with and without ALK-5 inhibitor.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: SB 525334

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > CD44HiSftpcC121Gs AT2s pathologically activate alveolar fibroblasts through TGF-β signaling (S108); Methods > Primary mouse AT2-only culture and analysis (S257); Methods > Primary mouse 2D culture (S263); Fig. 6 legend (S396, S398)

RT-qPCR gene expression of alveolar fibroblasts: RT-qPCR gene expression of alveolar fibroblasts; comparator: with and without ALK-5 inhibitor — Fig. 6 legend (S398)

In Vivo Studies

In male BALB/c mice with bleomycin-induced OSF, adding SB 525334 to bleomycin plus miR-17-5p agomir reversed the agomir-induced amplification of fibrosis, assessed by Masson staining. In the same treatment comparison, SB 525334 reversed the agomir-associated decrease in Smad7 expression, assessed by immunoblotting. [3]

Reversal of amplified fibrosis in bleomycin-induced OSF

Animal study · Male BALB/c mice; Bleomycin-induced OSF; n = 6 for each group [3]

Male BALB/c mice with bleomycin-induced OSF received treatment by intraperitoneal injection at 10 mg/kg daily for 2 weeks after 6 weeks of bleomycin treatment. Compared with bleomycin plus miR-17-5p agomir, adding SB 525334 reversed the agomir-induced amplification of fibrosis, assessed by collagen fraction in Masson staining.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification of Masson staining for collagen fractionReported result SB525334 effectively reversed the miR-17-5p-induced amplification of fibrosis[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
After 6 weeks of Bleomycin treatment; daily for 2 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SB 525334 10 mg/kgBleomycin + miR-17-5p agomirSB525334 effectively reversed the miR-17-5p-induced amplification of fibrosis[3]
SB 525334 10 mg/kg
Model: Male BALB/c mice; Bleomycin-induced OSF; n = 6 for each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: SB 525334

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Upregulation of miR-17-5p promotes OSF progression in mice (S94, S96); Materials and methods > Animal studies (S150, S155, S156, S157, S158); Fig. 9 legend (S216, S217, S219, S221)

Quantification of Masson staining for collagen fraction: Quantification of Masson staining for collagen fraction; comparator: Bleomycin + miR-17-5p agomir — Results > Upregulation of miR-17-5p promotes OSF progression in mice (S96); Fig. 9 legend (S219)

SB 525334 10 mg/kg · Results > Upregulation of miR-17-5p promotes OSF progression in mice (S96); Materials and methods > Animal studies (S156, S158)

SB525334 reversed this change in Smad7 expression

Animal study · Male BALB/c mice; Bleomycin-induced OSF; n = 6 for each group [3]

Male BALB/c mice with bleomycin-induced OSF received SB 525334 by intraperitoneal injection alongside bleomycin and miR-17-5p agomir. Compared with bleomycin plus agomir alone, SB 525334 reversed the agomir-associated decrease in Smad7 expression, assessed by immunoblotting.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Immunoblotting of fibrotic markers (Fibronectin, Collagen type I and α-SMA), Smad7, TGFBR1 and p-Smad2 pathwayReported result the expression of Smad7 was decreased in mice that were treated with the miR-17-5p agomir, whereas SB525334 reversed this change in Smad7 expression[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
After 6 weeks of Bleomycin treatment; daily for 2 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SB 525334 10 mg/kgBleomycin + miR-17-5p agomirthe expression of Smad7 was decreased in mice that were treated with the miR-17-5p agomir, whereas SB525334 reversed this change in Smad7 expression[3]
SB 525334 10 mg/kg
Model: Male BALB/c mice; Bleomycin-induced OSF; n = 6 for each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: SB 525334

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Upregulation of miR-17-5p promotes OSF progression in mice (S94, S99); Materials and methods > Animal studies (S150, S155, S156, S157, S158); Fig. 9 legend (S216, S220, S221)

Immunoblotting of fibrotic markers (Fibronectin, Collagen type I and α-SMA), Smad7, TGFBR1 and p-Smad2 pathway: Immunoblotting of fibrotic markers (Fibronectin, Collagen type I and α-SMA), Smad7, TGFBR1 and p-Smad2 pathway; comparator: Bleomycin + miR-17-5p agomir — Results > Upregulation of miR-17-5p promotes OSF progression in mice (S99); Fig. 9 legend (S220)

SB 525334 10 mg/kg · Results > Upregulation of miR-17-5p promotes OSF progression in mice (S99); Materials and methods > Animal studies (S156, S158)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 356559-20-1
Applications ALK Inhibitor
Formula C21H21N5
Molecular Weight 343.4
SMILES
CC1=CC=CC(=N1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=NC=CN=C4C=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 67 mg/mL (195.09 mM)
Water Insoluble
Ethanol 67 mg/mL (195.09 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
19 mg/mL
Vehicle
5% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Kaushik S, Juste YR, Lindenau K, et al. Chaperone-mediated autophagy regulates adipocyte differentiation. Sci Adv (2022). PMID: 36383673 DOI: 10.1126/sciadv.abq2733 Source material
  2. [2] Hoffman ET, Shah A, Barboza WR, et al. Aberrant intermediate alveolar epithelial cells promote pathogenic activation of lung fibroblasts in preclinical fibrosis models. Nat Commun (2025). PMID: 41027873 DOI: 10.1038/s41467-025-63735-1 Source material
  3. [3] Xie C, Zhong L, Feng H, et al. Exosomal miR-17-5p derived from epithelial cells is involved in aberrant epithelium-fibroblast crosstalk and induces the development of oral submucosal fibrosis. Int J Oral Sci (2024). PMID: 38897993 DOI: 10.1038/s41368-024-00302-2 Source material

Added to your cart

View Cart Checkout
Loading...